303 related articles for article (PubMed ID: 24265352)
1. Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma.
Ponzoni M; Issa S; Batchelor TT; Rubenstein JL
Ann Oncol; 2014 Feb; 25(2):316-22. PubMed ID: 24265352
[TBL] [Abstract][Full Text] [Related]
2. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma.
Zhao D; Qian L; Shen J; Liu X; Mei K; Cen J; Wang Y; Li C; Ma Y
J Cell Mol Med; 2014 Jun; 18(6):1081-6. PubMed ID: 24628986
[TBL] [Abstract][Full Text] [Related]
4. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
5. Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
Yamanaka R; Morii K; Shinbo Y; Takeuchi S; Tamura T; Hondoh H; Takahashi H; Onda K; Takahashi H; Tanaka R
Ann Hematol; 2005 Jul; 84(7):447-55. PubMed ID: 15747120
[TBL] [Abstract][Full Text] [Related]
6. Improved survival with combined chemo-radiotherapy in primary central nervous system lymphoma.
Abdelsalam M; El-Husseiny G; Akhtar S; Khafaga Y; Al-Shabana M; AlHusaini H; El Weshi A; Rahal M; Maghfoor I
Hematol Oncol Stem Cell Ther; 2010; 3(3):128-34. PubMed ID: 20890070
[TBL] [Abstract][Full Text] [Related]
7. Current status and future of relapsed primary central nervous system lymphoma (PCNSL).
Tyson RM; Siegal T; Doolittle ND; Lacy C; Kraemer DF; Neutwelt EA
Leuk Lymphoma; 2003 Apr; 44(4):627-33. PubMed ID: 12769339
[TBL] [Abstract][Full Text] [Related]
8. Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents.
Ferreri AJM
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):565-577. PubMed ID: 29222306
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Primary Central Nervous System Lymphoma with High-dose Methotrexate and Radiotherapy in HIV-negative Patients.
Jalaeikhoo H; Yekaninejad MS; Hajizamani S; Rahim F; Ahmadzadeh A; Keyhani M; Sadeghi Hariri B; Saki N
Arch Iran Med; 2015 Sep; 18(9):577-81. PubMed ID: 26317598
[TBL] [Abstract][Full Text] [Related]
10. Progress in central nervous system lymphomas.
Wang CC; Carnevale J; Rubenstein JL
Br J Haematol; 2014 Aug; 166(3):311-25. PubMed ID: 24837460
[TBL] [Abstract][Full Text] [Related]
11. Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice.
Deckert M; Montesinos-Rongen M; Brunn A; Siebert R
Acta Neuropathol; 2014 Feb; 127(2):175-88. PubMed ID: 24240734
[TBL] [Abstract][Full Text] [Related]
12. Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma.
Doolittle ND; Korfel A; Lubow MA; Schorb E; Schlegel U; Rogowski S; Fu R; Dósa E; Illerhaus G; Kraemer DF; Muldoon LL; Calabrese P; Hedrick N; Tyson RM; Jahnke K; Maron LM; Butler RW; Neuwelt EA
Neurology; 2013 Jul; 81(1):84-92. PubMed ID: 23685932
[TBL] [Abstract][Full Text] [Related]
13. A Rare Case of Primary Central Nervous System Lymphoma in an Adolescent Female Treated with High-Dose Methotrexate and Rituximab-Based Chemoimmunotherapy and Consolidation Whole Brain Radiotherapy.
Biswas A; Adhikari N; Bakhshi S; Gopinathan VR; Sharma MC
Pediatr Neurosurg; 2019; 54(1):57-65. PubMed ID: 30669145
[TBL] [Abstract][Full Text] [Related]
14. Metabolome Analysis Reveals Excessive Glycolysis via PI3K/AKT/mTOR and RAS/MAPK Signaling in Methotrexate-Resistant Primary CNS Lymphoma-Derived Cells.
Takashima Y; Hayano A; Yamanaka R
Clin Cancer Res; 2020 Jun; 26(11):2754-2766. PubMed ID: 32108030
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.
Green MR; Chowdhary S; Lombardi KM; Chalmers LM; Chamberlain M
Expert Rev Neurother; 2006 May; 6(5):635-52. PubMed ID: 16734512
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in treatment of primary central nervous system lymphoma.
Nayak L; Batchelor TT
Curr Treat Options Oncol; 2013 Dec; 14(4):539-52. PubMed ID: 23934511
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in primary CNS lymphoma.
Hoang-Xuan K; Camilleri-Broët S; Soussain C
Curr Opin Oncol; 2004 Nov; 16(6):601-6. PubMed ID: 15627024
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival in AIDS-related primary central nervous system lymphoma.
Gupta NK; Nolan A; Omuro A; Reid EG; Wang CC; Mannis G; Jaglal M; Chavez JC; Rubinstein PG; Griffin A; Abrams DI; Hwang J; Kaplan LD; Luce JA; Volberding P; Treseler PA; Rubenstein JL
Neuro Oncol; 2017 Jan; 19(1):99-108. PubMed ID: 27576871
[TBL] [Abstract][Full Text] [Related]
19. The prognostic role of CD68 and FoxP3 expression in patients with primary central nervous system lymphoma.
Cho H; Kim SH; Kim SJ; Chang JH; Yang WI; Suh CO; Cheong JW; Kim YR; Lee JY; Jang JE; Kim Y; Min YH; Kim JS
Ann Hematol; 2017 Jul; 96(7):1163-1173. PubMed ID: 28508176
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
